⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
NVS News
Novartis AG
John F. Crowley, President and CEO of the Biotechnology Innovation Organization (BIO), to Deliver Keynote Address on the Future of Biotech and Rare Disease Innovation at the 2026 MDA Clinical & Scientific Conference
globenewswire.com
AMGN
REGN
GILD
BMY
AZN
NVS
ARGX
BIIB
BBIO
SRRK
CAR T-Cell Therapy Market Industry Trends and Global Forecasts to 2035 by Target Antigens, Target Indication, Key Geographies, Sales Forecast of Drugs and Leading Players
globenewswire.com
BMY
GILD
NVS
Basal Cell Carcinoma Market Poised for Steady Growth Throughout Forecast Period (2025-2034) Driven by Novel Drug Approvals and Expanding Patient Pool | DelveInsight
prnewswire.com
VRCA
REGN
NVS
GENK
INCLUSION OF TINENGOTINIB TABLETS IN THE LIST OF PRODUCTS FOR PRIORITY REVIEW BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION
prnewswire.com
NVS
Actithera appoints radiopharmaceutical pioneer Dr. Darshan Dalal as Chief Medical Officer
globenewswire.com
AZN
NVS
Celltrion announces U.S. FDA approval of 300mg strength of OMLYCLO® (omalizumab-igec), the first and only FDA-approved interchangeable biosimilar to XOLAIR®
prnewswire.com
CRNX
NVS
Migraine Clinical Trial Pipeline Expands as 30+ Companies Driving Innovation in Oncology Therapeutics Space | DelveInsight
globenewswire.com
LUN
LLY
AMGN
NVS
TEVA
ALLER
BHVN
DRREDDY
ABBV
IMPL
ZSAN
AXSM
AEON
IONS
CHRC
AZN
GSK
WSTN
Comanche Biopharma Appoints Richard Colvin, MD, PhD as Global Head of R&D and John McHutchison, AO, MD as Chairman and Director of Comanche Biopharma Australia
globenewswire.com
CBIO
BBIO
NVS
TUNE
VELI
ASMB
GILD
Prescription Drugs Market Poised for Substantial Growth, Driven by Novel Therapies and Evolving Regulatory Landscape: Reaching US$2.15 Trillion by 2032
prnewswire.com
MRK
PFE
RO
NVS
SNY
Enterome OncoMimics™ immunotherapy EO2401 shows survival benefit in Phase 2 glioblastoma trial
globenewswire.com
NVS
BIIB